The Manufacturers Life Insurance Company Invests $92,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

The Manufacturers Life Insurance Company bought a new stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 12,488 shares of the company’s stock, valued at approximately $92,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new stake in shares of Actinium Pharmaceuticals in the second quarter valued at approximately $142,000. Rhumbline Advisers boosted its stake in Actinium Pharmaceuticals by 23.4% during the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the period. Squarepoint Ops LLC purchased a new position in Actinium Pharmaceuticals during the 2nd quarter worth $356,000. Bank of New York Mellon Corp grew its position in Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after purchasing an additional 19,035 shares during the last quarter. Finally, Virtu Financial LLC increased its stake in Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after purchasing an additional 62,459 shares during the period. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Performance

Shares of Actinium Pharmaceuticals stock opened at $1.82 on Monday. The firm has a 50-day moving average of $1.86. The stock has a market capitalization of $54.21 million, a PE ratio of -1.06 and a beta of 0.14. Actinium Pharmaceuticals, Inc. has a 12-month low of $1.33 and a 12-month high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.02. On average, research analysts predict that Actinium Pharmaceuticals, Inc. will post -1.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ATNM has been the subject of several recent research reports. StockNews.com upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 8th. Maxim Group dropped their target price on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. B. Riley cut Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $16.00 to $2.00 in a report on Wednesday, August 7th. Finally, HC Wainwright dropped their price objective on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Actinium Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $11.40.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).